<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: further disclosures", fill: "#36454f"},
{source: "6: further disclosures", target: "7: company which", fill: "#4f666a"},
{source: "7: company which", target: "7: corporation", fill: "#4f666a"},
{source: "7: corporation", target: "7: Province of Ontario ", fill: "#4f666a"},
{source: "7: Province of Ontario ", target: "7: continued as", fill: "#4f666a"},
{source: "7: continued as", target: "7: corporation under", fill: "#4f666a"},
{source: "7: corporation under", target: "7: State of Wyoming ", fill: "#4f666a"},
{source: "7: State of Wyoming ", target: "7: December ", fill: "#4f666a"},
{source: "7: December ", target: "7: stockholder approval", fill: "#4f666a"},
{source: "7: stockholder approval", target: "7: reincorporated", fill: "#4f666a"},
{source: "7: reincorporated", target: "7: Delaware ", fill: "#4f666a"},
{source: "7: company which", target: "18: significant risk factors known", fill: "#db7093"},
{source: "18: significant risk factors known", target: "18: could materially", fill: "#db7093"},
{source: "18: could materially", target: "18: adversely affect", fill: "#db7093"},
{source: "18: adversely affect", target: "18: financial condition", fill: "#db7093"},
{source: "18: significant risk factors known", target: "24: continuing losses", fill: "#c89"},
{source: "24: continuing losses", target: "24: development programs expand", fill: "#c89"},
{source: "24: development programs expand", target: "24: clinical trials commence", fill: "#c89"},
{source: "24: continuing losses", target: "25: depend on among", fill: "#89cff0"},
{source: "25: depend on among", target: "25: product development", fill: "#89cff0"},
{source: "25: product development", target: "25: development programs", fill: "#89cff0"},
{source: "25: development programs", target: "25: acquisition", fill: "#89cff0"},
{source: "25: acquisition", target: "25: new products", fill: "#89cff0"},
{source: "25: new products", target: "25: necessary regulatory", fill: "#89cff0"},
{source: "25: necessary regulatory", target: "25: third party", fill: "#89cff0"},
{source: "25: third party", target: "25: reimbursement", fill: "#89cff0"},
{source: "25: reimbursement", target: "25: marketing activities", fill: "#89cff0"},
{source: "25: marketing activities", target: "25: future products", fill: "#89cff0"},
{source: "25: future products", target: "25: future litigation", fill: "#89cff0"},
{source: "25: depend on among", target: "26: generate new", fill: "#49796b"},
{source: "26: generate new", target: "26: significant revenues", fill: "#49796b"},
{source: "26: significant revenues", target: "26: must successfully", fill: "#49796b"},
{source: "26: must successfully", target: "26: successfully", fill: "#49796b"},
{source: "26: successfully", target: "26: commercialize", fill: "#49796b"},
{source: "26: commercialize", target: "26: proposed products", fill: "#49796b"},
{source: "26: proposed products", target: "26: enter into", fill: "#49796b"},
{source: "26: enter into", target: "26: collaborative", fill: "#49796b"},
{source: "26: collaborative", target: "26: agreements with others", fill: "#49796b"},
{source: "26: generate new", target: "34: development", fill: "#039"},
{source: "34: development", target: "34: scope timing", fill: "#039"},
{source: "34: scope timing", target: "34: clinical trials", fill: "#039"},
{source: "34: clinical trials", target: "34: patient recruitment", fill: "#039"},
{source: "34: patient recruitment", target: "34: enrollment", fill: "#039"},
{source: "34: enrollment", target: "34: future clinical trials", fill: "#039"},
{source: "34: future clinical trials", target: "34: cost timing", fill: "#039"},
{source: "34: cost timing", target: "34: regulatory reviews", fill: "#039"},
{source: "34: regulatory reviews", target: "34: technological advances", fill: "#039"},
{source: "34: technological advances", target: "34: ongoing determinations", fill: "#039"},
{source: "34: ongoing determinations", target: "34: potential commercial", fill: "#039"},
{source: "34: potential commercial", target: "34: administrative expenses", fill: "#039"},
{source: "34: administrative expenses", target: "34: expenses incurred", fill: "#039"},
{source: "34: expenses incurred", target: "34: connection with pending", fill: "#039"},
{source: "34: connection with pending", target: "34: future litigation", fill: "#039"},
{source: "34: future litigation", target: "34: commercialize them ourselves", fill: "#039"},
{source: "34: commercialize them ourselves", target: "34: marketing capabilities", fill: "#039"},
{source: "34: marketing capabilities", target: "34: activities", fill: "#039"},
{source: "34: activities", target: "34: competitors", fill: "#039"},
{source: "34: competitors", target: "34: opportunities", fill: "#039"},
{source: "34: opportunities", target: "34: new products", fill: "#039"},
{source: "34: new products", target: "34: unanticipated opportunities", fill: "#039"},
{source: "34: development", target: "38: development", fill: "#808080"},
{source: "38: development", target: "38: operations", fill: "#808080"},
{source: "38: operations", target: "38: proposed products", fill: "#808080"},
{source: "38: proposed products", target: "38: risks inherent", fill: "#808080"},
{source: "38: risks inherent", target: "38: establishment", fill: "#808080"},
{source: "38: establishment", target: "38: commercialized products", fill: "#808080"},
{source: "38: commercialized products", target: "38: continual losses", fill: "#808080"},
{source: "38: continual losses", target: "38: foreseeable future", fill: "#808080"},
{source: "38: foreseeable future", target: "38: dealing with regulatory issues", fill: "#808080"},
{source: "38: dealing with regulatory issues", target: "38: manufacturing", fill: "#808080"},
{source: "38: manufacturing", target: "38: reliance on third parties", fill: "#808080"},
{source: "38: reliance on third parties", target: "38: commercialization", fill: "#808080"},
{source: "38: commercialization", target: "38: competitive environment characterized by numerous", fill: "#808080"},
{source: "38: competitive environment characterized by numerous", target: "38: uncertain market acceptance", fill: "#808080"},
{source: "38: uncertain market acceptance", target: "38: reliance on key personnel", fill: "#808080"},
{source: "38: development", target: "43: cannot assure", fill: "#b38b6d"},
{source: "43: cannot assure", target: "43: proposed products will", fill: "#b38b6d"},
{source: "43: proposed products will", target: "43: successfully", fill: "#b38b6d"},
{source: "43: successfully", target: "43: efficacious", fill: "#b38b6d"},
{source: "43: efficacious", target: "43: clinical trials", fill: "#b38b6d"},
{source: "43: clinical trials", target: "43: meet applicable regulatory standards", fill: "#b38b6d"},
{source: "43: meet applicable regulatory standards", target: "43: regulatory approvals", fill: "#b38b6d"},
{source: "43: regulatory approvals", target: "43: demonstrate", fill: "#b38b6d"},
{source: "43: demonstrate", target: "43: commercial quantities at", fill: "#b38b6d"},
{source: "43: commercial quantities at", target: "43: reasonable costs", fill: "#b38b6d"},
{source: "43: reasonable costs", target: "43: reimbursement rates from", fill: "#b38b6d"},
{source: "43: reimbursement rates from", target: "43: thirdparty payors", fill: "#b38b6d"},
{source: "43: thirdparty payors", target: "43: successfully marketed", fill: "#b38b6d"},
{source: "43: successfully marketed", target: "43: market acceptance by", fill: "#b38b6d"},
{source: "43: cannot assure", target: "44: regulatory approval", fill: "#ed9121"},
{source: "44: regulatory approval", target: "44: commercially manufacture", fill: "#ed9121"},
{source: "44: commercially manufacture", target: "44: future products", fill: "#ed9121"},
{source: "44: future products", target: "44: generate revenue from", fill: "#ed9121"},
{source: "44: regulatory approval", target: "START_HERE", fill: "#ed9121"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Internet Software and Services</td>
    </tr>
    <tr>
      <td>Internet Retail</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots. Italy still prohibits offensive strikes, and reserves the right to veto U.S. missions.2 JanuaryIndian aerial surveillance detected gunmen entering an Indian Air Force base at Pathankot, and their security forces exchange fire with them in a housing area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_differentiation">Product differentiation</a></td>
      <td>In economics and marketing, product differentiation (or simply differentiation) is  \nthe process of distinguishing a product or service from others, to make it more attractive to a particular target market. This involves differentiating it from competitors' products as well as a firm's own products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Structured_product">Structured product</a></td>
      <td>A structured product, also known as a market-linked investment, is a pre-packaged structured finance investment strategy based on a single security, a basket of securities, options, indices, commodities, debt issuance or foreign currencies, and to a lesser extent, derivatives.\nStructured products are not homogeneous — there are numerous varieties of derivatives and underlying assets — but they can be classified under the aside categories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Carbon_Border_Adjustment_Mechanism">Carbon Border Adjustment Mechanism</a></td>
      <td>The Carbon Border Adjustment Mechanism (CBAM) is a proposed carbon tariff on carbon intensive products, such as cement and some electricity, imported by the European Union. Currently being legislated as part of the European Green Deal it is likely to take effect in 2026 with reporting starting in 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Starlink">Starlink</a></td>
      <td>Starlings are small to medium-sized passerine birds in the family Sturnidae. The name "Sturnidae" comes from the Latin word for starling, sturnus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proton-pump_inhibitor">Proton-pump inhibitor</a></td>
      <td>Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump.They are the most potent inhibitors of acid secretion available.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency">Medicines and Healthcare products Regulatory Agency</a></td>
      <td>The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.\nThe MHRA was formed in 2003 with the merger of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Denosumab">Denosumab</a></td>
      <td>Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand), which works by preventing the development of osteoclasts, which are cells that break down bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gilead_Sciences">Gilead Sciences</a></td>
      <td>Gilead Sciences, Inc. , is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BIOSANTE PHARMACEUTICALS INC      “Item  1A <font color="blue">Risk Factors</font>” below, <font color="blue">as well as others</font> that we may consider     immaterial or do not anticipate at this time</td>
    </tr>
    <tr>
      <td>Although we believe that the     <font color="blue"><font color="blue">expectations</font> reflected</font> in our forward-looking statements are reasonable, we     do not know whether our <font color="blue"><font color="blue">expectations</font> will prove</font> correct</td>
    </tr>
    <tr>
      <td>Our <font color="blue">expectations</font>     reflected in our forward-looking statements can be <font color="blue">affected by inaccurate</font>     <font color="blue">assumptions</font> we might make or by known or <font color="blue">unknown risks</font> and <font color="blue">uncertainties</font>,     including those described below under the heading “Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>”     The risks and <font color="blue">uncertainties</font> described under the heading “Item 1A Risk     Factors” below are not exclusive and further information <font color="blue">concerning us</font> and     our business, including factors that <font color="blue">potentially <font color="blue">could materially</font> affect</font> our     financial results or condition, may emerge from time to time</td>
    </tr>
    <tr>
      <td>We assume no     <font color="blue">obligation</font> to update forward-looking statements to <font color="blue">reflect actual</font> results or     changes in factors or <font color="blue">assumptions</font> affecting such forward-looking statements</td>
    </tr>
    <tr>
      <td>We  advise you, however, to consult any <font color="blue">further disclosures</font> we make on     related subjects in our quarterly reports on Form 10-Q and current reports     on  Form 8-K  we  file  with or furnish to the <font color="blue">Securities </font>and Exchange     Commission</td>
    </tr>
    <tr>
      <td>Available Information           Our company, which was initially formed as a <font color="blue">corporation</font> organized under the     laws of the <font color="blue">Province of Ontario </font>on August 29, 1996, was <font color="blue">continued as</font> a     <font color="blue">corporation</font> under the laws of the <font color="blue">State of Wyoming </font>on <font color="blue">December </font>19, 1996 and     pursuant to <font color="blue">stockholder approval</font> was <font color="blue">reincorporated</font> in <font color="blue">Delaware </font>on June 26,     2001</td>
    </tr>
    <tr>
      <td>Our  company  is  the  continuing <font color="blue">corporation</font> resulting from an     <font color="blue">amalgamation</font>, or <font color="blue">consolidation</font>, of <font color="blue">three companies</font> — our company, which was     <font color="blue"><font color="blue">previously</font> named</font> “Ben-Abraham Technologies Inc,” <font color="blue">Structured Biologicals</font>     Inc, a <font color="blue">corporation</font> organized under the laws of the Province of Ontario, and     923934 Ontario Inc, a <font color="blue">corporation</font> organized under the laws of the Province     of Ontario and a wholly owned subsidiary of <font color="blue">Structured Biologicals</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">amalgamation</font> was <font color="blue">approved by</font> our <font color="blue">stockholders on</font> November 27, 1996 and the     articles of <font color="blue">arrangement</font> were filed and <font color="blue">became <font color="blue">effective</font> as</font> of <font color="blue">December </font>6,     1996</td>
    </tr>
    <tr>
      <td>In  November 1999,  our <font color="blue">stockholders approved</font> the change of our     corporate   name   from  Ben-Abraham  Technologies  Inc</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">principal executive offices</font> are located at 111 Barclay Boulevard,     Lincolnshire, Illinois 60069</td>
    </tr>
    <tr>
      <td>Our telephone number is (847) 478-0500, and     our Internet <font color="blue">web site address</font> is www</td>
    </tr>
    <tr>
      <td>The information     <font color="blue">contained on</font> our web site or connected to our website is not <font color="blue">incorporated by</font>     <font color="blue">reference into</font> and should not be considered part of this annual report on     Form 10-K         We make available, free of charge and through our Internet web site, our     annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports     on Form 8-K, and any <font color="blue">amendments</font> to any such reports filed or furnished     pursuant to Section 13(a) or 15(d) of the <font color="blue"><font color="blue">Securities </font><font color="blue">Exchange Act</font> </font>of 1934 as     soon as <font color="blue">reasonably</font> practicable after we <font color="blue">electronically</font> file such material     with, or furnish it to, the SEC We also make available, free of charge and     through  our  <font color="blue">Internet  </font>web site, to any stockholder who requests, our     <font color="blue">corporate governance guidelines</font>, the charters of our <font color="blue">board committees</font> and     our <font color="blue">Code of Conduct and Ethics</font></td>
    </tr>
    <tr>
      <td>Requests for copies can be directed to     <font color="blue">Investor Relations </font>at (847) 478-0500 x120</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________      Item 1A         RISK FACTORS           The following are <font color="blue"><font color="blue">significant</font> risk factors known</font> to us that <font color="blue">could materially</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font> or operating results</td>
    </tr>
    <tr>
      <td>We  have  a  history of operating losses, expect <font color="blue">continuing losses</font> and     may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have incurred losses in <font color="blue">each year since</font> our <font color="blue">amalgamation</font> in 1996 and     expect  to incur substantial and <font color="blue">continuing losses</font> for the foreseeable     future</td>
    </tr>
    <tr>
      <td>We incurred a net loss of dlra9cmam651cmam036 for the year ended <font color="blue">December </font>31,     2005, and as of <font color="blue">December </font>31, 2005, our <font color="blue">accumulated deficit</font> was dlra49cmam688cmam320</td>
    </tr>
    <tr>
      <td>All of our revenue to date has been <font color="blue">derived from</font> upfront and milestone     payments earned on licensing and sub-licensing <font color="blue">transactions</font> and revenue     earned from <font color="blue">subcontracts</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue"><font color="blue">commercially</font> introduced</font> any products</td>
    </tr>
    <tr>
      <td>We expect to incur substantial and <font color="blue">continuing losses</font> for the foreseeable     future  as  our  own  product  <font color="blue"><font color="blue"><font color="blue">development</font> programs</font> expand</font> and various     preclinical  and  <font color="blue"><font color="blue">clinical trials</font> commence</font></td>
    </tr>
    <tr>
      <td>The amount of these losses     may vary <font color="blue"><font color="blue">significant</font>ly</font> from year-to-year and quarter-to-quarter and will     depend on, among other factors:         •                  the timing and cost of <font color="blue">product <font color="blue">development</font></font>;         •                   the  progress and cost of preclinical and clinical     <font color="blue"><font color="blue">development</font> programs</font>;         •                  the costs of licensure or <font color="blue">acquisition</font> of <font color="blue">new products</font>;         •                  the timing and cost of obtaining <font color="blue"><font color="blue">necessary</font> <font color="blue">regulatory</font></font>     approvals;         •                   the  timing  and  cost  of  obtaining  <font color="blue">third party</font>     <font color="blue">reimbursement</font>;         •                  the timing and cost of sales and <font color="blue">marketing <font color="blue">activities</font></font> for     <font color="blue">future products</font>; and         •                  the costs of pending and any <font color="blue">future <font color="blue">litigation</font></font> of which     we may be subject</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">generate new</font> and <font color="blue"><font color="blue">significant</font> revenues</font>, we <font color="blue">must <font color="blue">successfully</font></font>     develop  and  <font color="blue">commercialize</font>  our  own  <font color="blue"><font color="blue">proposed product</font>s</font> or <font color="blue">enter into</font>     <font color="blue">collaborative</font>  <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with others</font> who can <font color="blue">successfully</font> develop and     <font color="blue">commercialize</font>  them</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue"><font color="blue">proposed product</font>s</font> and the products we     may license or otherwise acquire are <font color="blue"><font color="blue">commercially</font> introduced</font>, they may never     achieve <font color="blue">market <font color="blue">acceptance</font></font> and we may never generate <font color="blue"><font color="blue">significant</font> revenues</font> or     achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We will need to raise substantial <font color="blue"><font color="blue">additional</font> capital</font> in the future to fund     our <font color="blue">operations</font> and we may be unable to <font color="blue">raise such funds</font> when needed and on     acceptable terms</td>
    </tr>
    <tr>
      <td>We  currently  do  not  have  sufficient  resources  to  complete  the     <font color="blue">commercialization</font> of any of our <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>Therefore, we will need     to raise substantial <font color="blue"><font color="blue">additional</font> capital</font> to fund our <font color="blue">operations</font> sometime in     the future</td>
    </tr>
    <tr>
      <td>Based on our <font color="blue">current rate</font> of cash outflows, we believe that our     cash and short-term <font color="blue">investment</font>s of dlra9cmam101cmam531 at <font color="blue">December </font>31, 2005, will be     sufficient  to meet our anticipated cash needs for working capital and     <font color="blue">capital expenditures</font> for at least the next 12 months</td>
    </tr>
    <tr>
      <td>We have based this     estimate on <font color="blue">assumptions</font>, however, that may prove to be wrong</td>
    </tr>
    <tr>
      <td>As a result,     we may need to obtain <font color="blue">additional</font> financing prior to that time</td>
    </tr>
    <tr>
      <td>Our future     capital <font color="blue">requirements</font> will depend upon numerous factors, including:         •                  the progress and costs of our research and <font color="blue">development</font>     programs;                                           22     ______________________________________________________________________         •                  the scope, timing and results of our <font color="blue">clinical trials</font>;         •                  <font color="blue">patient recruitment</font> and <font color="blue">enrollment</font> in our current and     future <font color="blue">clinical trials</font>;         •                  the cost, timing and outcome of <font color="blue"><font color="blue">regulatory</font> reviews</font>;         •                  the rate of <font color="blue">technological advances</font>;         •                   <font color="blue">ongoing de<font color="blue">termination</font>s</font> of the <font color="blue">potential commercial</font>     success of our <font color="blue"><font color="blue">proposed product</font>s</font>;         •                  our general and <font color="blue">administrative expenses</font>, including legal     <font color="blue">expenses incurred</font> in <font color="blue">connection with pending</font> any and <font color="blue">future <font color="blue">litigation</font></font> of     which we may be subject;         •                   if  we receive FDA approval of any of our proposed     products and choose to <font color="blue">commercialize</font> them ourselves, the amount of resources     we devote to sales and <font color="blue">marketing capabilities</font>;         •                  the <font color="blue">activities</font> of our <font color="blue">competitors</font>; and         •                   our  <font color="blue">opportunities</font> to acquire <font color="blue">new products</font> or take     advantage of other unanticipated <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that any <font color="blue">financing will</font> be available when needed or     will be on terms acceptable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient </font>funds may require us to     delay, scale back or eliminate some or all of our <font color="blue">programs designed</font> to     obtain  <font color="blue">regulatory</font>  approval  of our <font color="blue"><font color="blue">proposed product</font>s</font>, facilitate the     commercial  <font color="blue">introduction</font>  of our <font color="blue"><font color="blue">proposed product</font>s</font>, prevent commercial     <font color="blue">introduction</font> of our <font color="blue">products altogether</font> or <font color="blue">restrict us from</font> acquiring new     products that we believe may be <font color="blue">beneficial</font> to our business</td>
    </tr>
    <tr>
      <td>We are a <font color="blue">development</font> stage company, making it <font color="blue">difficult</font> for you to evaluate     our business and your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We are in the <font color="blue">development</font> stage and our <font color="blue">operations</font> and the <font color="blue">development</font> of     our  <font color="blue"><font color="blue">proposed product</font>s</font> are subject to all of the <font color="blue">risks inherent</font> in the     <font color="blue">establishment</font> of a new business enterprise, including:         •                  the absence of an operating history;         •                  the lack of <font color="blue">commercialize</font>d products;         •                  insufficient capital;         •                   expected  substantial and <font color="blue">continual losses</font> for the     <font color="blue">foreseeable future</font>;         •                  limited experience in dealing with <font color="blue">regulatory</font> issues;         •                  limited marketing and <font color="blue">manufacturing</font> experience;         •                  an expected <font color="blue">reliance on <font color="blue">third parties</font></font> for the <font color="blue">development</font>     and <font color="blue">commercialization</font> of some of our <font color="blue"><font color="blue">proposed product</font>s</font>;         •                  a <font color="blue"><font color="blue">competitive</font> environment characterized by numerous</font>,     well-established and well-capitalized <font color="blue">competitors</font>;         •                  uncertain <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue"><font color="blue">proposed product</font>s</font>; and                                           23     ______________________________________________________________________         •                  <font color="blue">reliance on key personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  are subject to these risks, you may have a <font color="blue">difficult</font> time     evaluating our business and your <font color="blue">investment</font> in our company</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">proposed product</font>s</font> are in the <font color="blue">development</font> stages and <font color="blue">will likely</font> not be     <font color="blue"><font color="blue">commercially</font> introduced</font> for one or more years, if at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">proposed product</font>s</font> are in the <font color="blue">development</font> stages and will require further     <font color="blue">development</font>,  preclinical and <font color="blue">clinical testing</font> and <font color="blue">investment</font> prior to     <font color="blue">commercialization</font> in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commercially</font>     introduced any products and do not expect to do so until early 2007 at the     <font color="blue">earliest depending upon</font> the timing of the FDA’s <font color="blue">decision on</font> our New Drug     Application for our Bio-E-Gel <font color="blue">product which</font> was submitted in <font color="blue">February </font>2006     and the approval of <font color="blue">such <font color="blue">application</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our     <font color="blue"><font color="blue">proposed product</font>s</font> will:         •                  be <font color="blue">successfully</font> developed;         •                  prove to be safe and <font color="blue">efficacious</font> in <font color="blue">clinical trials</font>;         •                  meet applicable <font color="blue">regulatory</font> standards or obtain required     <font color="blue">regulatory</font> approvals;         •                   <font color="blue">demonstrate</font>  substantial protective or therapeutic     benefits in the prevention or treatment of any disease;         •                  be capable of being produced in <font color="blue">commercial quantities at</font>     <font color="blue">reasonable costs</font>;         •                  obtain coverage and favorable <font color="blue">reimbursement</font> rates from     insurers and other third-party payors; or         •                  be <font color="blue">successfully</font> marketed or achieve <font color="blue">market <font color="blue">acceptance</font></font> by     physicians and patients</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">regulatory</font> approval to <font color="blue">commercially</font> <font color="blue">manufacture</font> or sell     any of our <font color="blue">future products</font>, or if approval is delayed or withdrawn, we will     be unable to <font color="blue">generate revenue from</font> the sale of our products</td>
    </tr>
    <tr>
      <td>We must obtain <font color="blue">regulatory</font> approval to sell any of our products in the United     States and abroad</td>
    </tr>
    <tr>
      <td>In the United States, we must obtain the approval of the     FDA  for each product or drug that we intend to <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font><font color="blue">approval process</font> is <font color="blue">typically lengthy</font> and expensive, and approval is never     certain</td>
    </tr>
    <tr>
      <td>Products to be <font color="blue">commercialize</font>d abroad are subject to similar foreign     <font color="blue">government</font> regulation</td>
    </tr>
    <tr>
      <td>Generally, only a very small percentage of <font color="blue">newly discovered <font color="blue">pharmaceutical</font></font>     products that enter preclinical <font color="blue">development</font> are approved for sale</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>   of  the  risks and <font color="blue">uncertainties</font> in <font color="blue">bio<font color="blue">pharmaceutical</font></font> <font color="blue">development</font>, our     <font color="blue"><font color="blue">proposed product</font>s</font> could take a <font color="blue"><font color="blue">significant</font>ly</font> longer time to gain <font color="blue">regulatory</font>     approval than we expect or may never gain approval</td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font> approval     is delayed or never obtained, our <font color="blue">management</font>’s credibility, the value of our     company and our operating results and <font color="blue">liquidity would</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Furthermore, even if a product gains <font color="blue">regulatory</font> approval, the product and     the <font color="blue"><font color="blue">manufacture</font>r</font> of the <font color="blue">product may</font> be subject to continuing <font color="blue">regulatory</font>     review</td>
    </tr>
    <tr>
      <td>Even after obtaining <font color="blue">regulatory</font> approval, we may be restricted or     <font color="blue"><font color="blue">prohibited from</font> marketing</font> or <font color="blue">manufacturing</font> a product if <font color="blue"><font color="blue">previously</font> unknown</font>     <font color="blue">problems with</font> the product or its <font color="blue">manufacture</font> are <font color="blue">subsequently discovered</font></td>
    </tr>
    <tr>
      <td>The FDA may also require us to commit to perform lengthy post-approval     studies, for which we would                                           24     ______________________________________________________________________         have to expend <font color="blue">significant</font> <font color="blue">additional</font> resources, which could have an adverse     effect on our operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>To obtain <font color="blue">regulatory</font> approval to market our products, costly and lengthy     pre-clinical studies and human <font color="blue">clinical trials</font> are required, and the results     of the studies and trials are <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>As part of the FDA <font color="blue">approval process</font>, we must conduct, at our own expense or     the expense of current or potential licensees, <font color="blue">clinical trials</font> on humans on     each of our <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>Pre-clinical <font color="blue">studies on animals must</font> be     conducted  on  some  of our <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>We expect the number of     pre-clinical studies and human <font color="blue">clinical trials</font> that the FDA will require     <font color="blue">will vary depending on</font> the product, the disease or condition the product is     being developed to address and <font color="blue"><font color="blue">regulations</font> applicable</font> to the particular     product</td>
    </tr>
    <tr>
      <td>We may need to perform multiple pre-clinical studies using various     doses and <font color="blue">formulations</font> before we can begin human <font color="blue">clinical trials</font>, which     could  result  in delays in our ability to market any of our products</td>
    </tr>
    <tr>
      <td>Furthermore, even if we obtain favorable results in pre-clinical studies on     animals, the results in <font color="blue">humans may</font> be <font color="blue">different</font></td>
    </tr>
    <tr>
      <td>After we have conducted pre-clinical studies in animals, we must <font color="blue">demonstrate</font>     that  our  products are safe and <font color="blue">effective</font> for use on the <font color="blue">target human</font>     patients in order to receive <font color="blue">regulatory</font> approval for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>The     data obtained from pre-clinical and human <font color="blue">clinical testing</font> are subject to     varying  <font color="blue">interpretations</font> that could delay, limit or prevent <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>We face the risk that the results of our <font color="blue">clinical trials</font> in later     phases of <font color="blue">clinical trials</font> may be <font color="blue">inconsistent with</font> those obtained in earlier     phases</td>
    </tr>
    <tr>
      <td>A  number of companies in the <font color="blue">bio<font color="blue">pharmaceutical</font></font> industry have     suffered  <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue">clinical trials</font>, even after     experiencing promising results in <font color="blue">early animal</font> or <font color="blue">human testing</font></td>
    </tr>
    <tr>
      <td>Adverse or     <font color="blue">inconclusive</font>  human  clinical results would prevent us from filing for     <font color="blue">regulatory</font> approval of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>factors that can cause delay     or <font color="blue">termination</font> of our human <font color="blue">clinical trials</font> include:         •                  slow patient <font color="blue">enrollment</font>;         •                  timely <font color="blue">completion</font> of <font color="blue">clinical site protocol approval</font> and     obtaining <font color="blue">informed consent from subjects</font>;         •                  <font color="blue">longer treatment</font> time required to <font color="blue">demonstrate</font> efficacy or     safety;         •                   adverse  <font color="blue">medical events</font> or side effects in treated     patients; and         •                  lack of <font color="blue">effective</font>ness of the product being tested</td>
    </tr>
    <tr>
      <td>Delays in our <font color="blue">clinical trials</font> could allow our <font color="blue">competitors</font> <font color="blue">additional</font> time to     develop or market competing products and thus can be extremely costly in     terms of lost sales <font color="blue">opportunities</font> and increased clinical trial costs</td>
    </tr>
    <tr>
      <td>A <font color="blue">request by</font> an FDA <font color="blue">advisory committee</font> for <font color="blue">additional</font> safety data which     may require Procter &amp; Gamble to conduct <font color="blue">additional</font> studies to learn more     about the long-term safety of <font color="blue">testosterone</font> treatment in women for FSD prior     to <font color="blue">granting approval</font> of Procter &amp; Gamble’s Intrinsa <font color="blue">testosterone</font> patch could     increase the time, cost and expense of obtaining <font color="blue">regulatory</font> approval for our     LibiGel product, which might cause us to abandon the <font color="blue">product depending on</font>     the extent of the <font color="blue">additional</font> time and cost to develop LibiGel</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the FDA’s Reproductive Health Drugs Advisory Committee     <font color="blue">panel voted unanimously against <font color="blue">recommendation</font></font> for approval of Procter &amp;     Gamble’s Intrinsa <font color="blue">testosterone</font> patch for <font color="blue">hypoactive sexual</font> desire disorder</td>
    </tr>
    <tr>
      <td>The  panel’s main concern was the desire to have long-term safety data     <font color="blue">particularly</font>                                           25     ______________________________________________________________________         as it pertains to <font color="blue">potential <font color="blue">increased risk</font></font> of <font color="blue">cardiovascular disease</font> and     <font color="blue">breast cancer</font> in women treated chronically with <font color="blue">testosterone</font> in <font color="blue">combination</font>     <font color="blue">with estrogen</font></td>
    </tr>
    <tr>
      <td>Currently, the FDA has not <font color="blue">explicitly publicly</font> stated nor set     any type of <font color="blue">public policy</font> or <font color="blue">guidance document as</font> to what size or duration     of a <font color="blue">safety trial would</font> be required for approval</td>
    </tr>
    <tr>
      <td>This FDA <font color="blue">action with</font>     respect to Intrinsa or <font color="blue">testosterone</font> products in general may affect the     <font color="blue">regulatory</font> pathway for our LibiGel product, as well as other similarly     <font color="blue"><font color="blue">competitive</font> products</font> to treat HSDD with <font color="blue">testosterone</font> therapy</td>
    </tr>
    <tr>
      <td>The FDA’s     final  <font color="blue">decision could increase</font> the time, cost and expense of obtaining     <font color="blue">regulatory</font> approval for our LibiGel product, which might cause us to delay     or abandon further <font color="blue">development</font> of the <font color="blue">product depending on</font> the extent of the     <font color="blue">additional</font> time and cost to develop LibiGel</td>
    </tr>
    <tr>
      <td>Several <font color="blue"><font color="blue">pharmaceutical</font> products</font> have <font color="blue">been found</font> to have <font color="blue">potentially life</font>     <font color="blue">threatening</font> side effects and have <font color="blue">been subsequently removed from</font> the market</td>
    </tr>
    <tr>
      <td>These  drugs  had  been  <font color="blue">previously</font>  approved for sale by the <font color="blue">FDA The     </font><font color="blue">withdrawals</font> of <font color="blue">approved drugs from</font> the market create an <font color="blue">increased risk</font> for     the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> in general in that certain <font color="blue"><font color="blue">proposed product</font>s</font>     may not receive the required <font color="blue">regulatory</font> approval on a <font color="blue">timely basis</font> or ever</td>
    </tr>
    <tr>
      <td>has increased safety concerns     of <font color="blue">various groups</font> including physicians, patients, members of US Congress     and the FDA Although marketed product <font color="blue">withdrawals</font> have occurred over time,     these  <font color="blue">withdrawals</font>  have resulted and <font color="blue">may continue</font> to result in a more     <font color="blue">cautious approach by</font> the FDA in terms of <font color="blue">requirements</font> for approval of new     products before approval to market is granted</td>
    </tr>
    <tr>
      <td>These recent <font color="blue">withdrawals</font>     <font color="blue">could also</font> result in <font color="blue">additional</font> <font color="blue">requirements</font> for <font color="blue">safety monitoring called</font>     <font color="blue">pharmacovigilence</font> after approval to market is granted</td>
    </tr>
    <tr>
      <td>This <font color="blue">collective</font>     concern  could result in longer, more expensive <font color="blue">clinical trials</font> before     approval and costly post-marketing surveillance programs and at the same     time <font color="blue">could affect physicians</font>’ desire to <font color="blue">prescribe new medication</font> before they     are on the market for a long period of time, all of <font color="blue">which would <font color="blue">adversely</font></font>     affect our business, operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font><font color="blue">associated with</font> the impact of <font color="blue">published studies</font> regarding the     <font color="blue">adverse health effects</font> of <font color="blue">certain forms</font> of <font color="blue"><font color="blue">hormone therapy</font> could <font color="blue">adversely</font></font>     affect the market for <font color="blue"><font color="blue">hormone therapy</font> products</font> and the <font color="blue">trading price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue"><font color="blue">hormone therapy</font> products</font> has <font color="blue">been negatively affected by</font> the     Women’s Health Initiative study and other studies that have found that the     <font color="blue">overall health risks from</font> the use of certain <font color="blue"><font color="blue">hormone therapy</font> products</font> exceed     the <font color="blue">benefits from</font> the use of those <font color="blue">products among healthy postmenopausal</font>     women</td>
    </tr>
    <tr>
      <td>In July 2002, the National Institutes of Health (NIH) <font color="blue">released data</font>     from its Women’s Health Initiative (WHI) study on the risks and benefits     <font color="blue">associated with</font> long-term use of <font color="blue">oral <font color="blue">hormone therapy</font> by healthy women</font></td>
    </tr>
    <tr>
      <td>The     NIH announced that it was <font color="blue">discontinuing</font> the arm of the study investigating     the use of oral estrogen/progestin <font color="blue">combination</font> <font color="blue"><font color="blue">hormone therapy</font> products</font>     after an average follow-up period of 5dtta2 years because the <font color="blue">product used</font> in     the study was shown to cause an increase in the risk of <font color="blue">invasive breast</font>     cancer</td>
    </tr>
    <tr>
      <td>The <font color="blue">study also found</font> an <font color="blue">increased risk</font> of stroke, heart attacks and     <font color="blue">blood clots</font> and concluded that overall health risks exceeded <font color="blue">benefits from</font>     use of <font color="blue">combined estrogen plus progestin</font> for an average of 5dtta2 year follow-up     among  healthy  <font color="blue">postmenopausal women</font></td>
    </tr>
    <tr>
      <td><font color="blue">Also in July </font>2002, results of an     <font color="blue">observational</font>  <font color="blue">study sponsored by</font> the <font color="blue">National Cancer Institute </font>on the     effects of <font color="blue">estrogen therapy</font> were announced</td>
    </tr>
    <tr>
      <td>The <font color="blue">main finding</font> of the study     was that <font color="blue">postmenopausal women</font> who used <font color="blue">estrogen therapy</font> for 10 or more years     had a <font color="blue">higher risk</font> of developing <font color="blue">ovarian cancer than women</font> who never used     <font color="blue">hormone therapy</font></td>
    </tr>
    <tr>
      <td>In October 2002, a <font color="blue">significant</font> <font color="blue">hormone therapy</font> study being     conducted  in the <font color="blue">United Kingdom </font>was also halted</td>
    </tr>
    <tr>
      <td>Our <font color="blue">proposed hormone</font>     therapy  products  <font color="blue">differ from</font> the <font color="blue">products used</font> in the Women’s Health     Initiative study and the <font color="blue">primary products</font> observed in the National Cancer     Institute and <font color="blue">United Kingdom </font>studies</td>
    </tr>
    <tr>
      <td>In March 2004, the NIH announced that     the estrogen-alone study was <font color="blue">discontinued</font> after <font color="blue">nearly seven years</font> because     the NIH concluded that <font color="blue">estrogen alone</font> does not affect (either increase or     decrease) heart disease, the <font color="blue">major question</font> being evaluated in the study</td>
    </tr>
    <tr>
      <td>The <font color="blue">findings indicated</font> a slightly <font color="blue">increased risk</font> of <font color="blue">stroke as well as</font> a     <font color="blue">decreased risk</font> of <font color="blue">hip fracture</font> and <font color="blue">breast cancer</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preliminary </font>data from the     memory portion of the WHI study suggested that <font color="blue">estrogen alone</font> may possibly     be <font color="blue">associated with</font> a slight                                           26     ______________________________________________________________________         increase in the risk of dementia or <font color="blue">mild cognitive impairment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Researchers     </font>continue to <font color="blue">analyze data from both arms</font> of the WHI study and other studies</td>
    </tr>
    <tr>
      <td>Recent reports indicate that the safety of <font color="blue">estrogen products may</font> be affected     by the age of the <font color="blue">woman at initiation</font> of therapy</td>
    </tr>
    <tr>
      <td>There currently are no     <font color="blue">studies published comparing</font> the safety of our proposed <font color="blue">hormone therapy</font>     <font color="blue">products against</font> other <font color="blue">hormone therapies</font></td>
    </tr>
    <tr>
      <td>The markets for <font color="blue">female hormone</font>     therapies  for  <font color="blue">menopausal symptoms</font> have <font color="blue">declined as</font> a result of these     <font color="blue">published studies</font></td>
    </tr>
    <tr>
      <td>The release of any follow-up or other studies that show     adverse affects from <font color="blue">hormone therapy</font>, including in particular, hormone     therapies similar to our <font color="blue"><font color="blue">proposed product</font>s</font>, would also <font color="blue"><font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td>Because our industry is very <font color="blue">competitive</font> and many of our <font color="blue">competitors</font> have     <font color="blue"><font color="blue">substantially</font> greater capital resources</font> and more experience in research and     <font color="blue">development</font>, <font color="blue">manufacturing</font> and marketing than us, we may not succeed in     developing our <font color="blue"><font color="blue">proposed product</font>s</font> and <font color="blue">bringing them</font> to market</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is intense</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">competitors</font>     in the <font color="blue">United States </font>and abroad are numerous and include <font color="blue">pharmaceutical</font>,     chemical and <font color="blue">bio<font color="blue">technology</font></font> companies, most of which have <font color="blue">substantially</font>     greater capital resources and more experience in research and <font color="blue">development</font>,     <font color="blue">manufacturing</font> and marketing than us</td>
    </tr>
    <tr>
      <td><font color="blue">Academic </font>institutions, hospitals,     <font color="blue">government</font>al agencies and other public and <font color="blue">private research organizations</font>     are <font color="blue">also conducting research</font> and <font color="blue">seeking patent protection</font> and may develop     and <font color="blue">commercially</font> introduce competing products or <font color="blue"><font color="blue">technologies</font> on</font> their own     or <font color="blue">through joint ventures</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">competitors</font> (some     of whom are our <font color="blue">development</font> partners) will not succeed in developing similar     <font color="blue">technologies</font> and products more <font color="blue">rapidly than</font> we do, <font color="blue">commercially</font> introducing     such <font color="blue">technologies</font> and products to the <font color="blue">marketplace prior than us</font>, or that     these competing <font color="blue">technologies</font> and <font color="blue">products will</font> not be more <font color="blue">effective</font> or     successful  than any of those that we currently are developing or will     develop</td>
    </tr>
    <tr>
      <td>We license the <font color="blue"><font color="blue"><font color="blue">technology</font> underlying</font> most</font> of our proposed <font color="blue">hormone therapy</font>     products and a portion of our CaP <font color="blue"><font color="blue"><font color="blue">technology</font> from</font> <font color="blue">third parties</font></font> and may lose     the rights to license them, which could have a material adverse effect on     our business, <font color="blue">financial position</font> and operating results and could cause the     <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">license most</font> of the <font color="blue"><font color="blue">technology</font> underlying</font> our proposed <font color="blue">hormone therapy</font>     <font color="blue">products from</font> Antares Pharma, Inc</td>
    </tr>
    <tr>
      <td>and a portion of our CaP <font color="blue"><font color="blue">technology</font> from</font>     the  <font color="blue">University </font> of California</td>
    </tr>
    <tr>
      <td>We may lose our right to license these     <font color="blue">technologies</font> if we breach our <font color="blue">obligation</font>s under the <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  intend  to use our <font color="blue">reasonable best efforts</font> to meet these     <font color="blue">obligation</font>s, if we violate or fail to perform any term or covenant of the     <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> or <font color="blue">with respect</font> to the <font color="blue">University </font>of California’s license     <font color="blue">agreement</font>  within  60 days after written notice from the <font color="blue">University </font>of     California,  the  other  party to these <font color="blue"><font color="blue">agreement</font>s</font> may terminate these     <font color="blue"><font color="blue">agreement</font>s</font>  or  certain  projects  contained  in these <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">termination</font>  of  these <font color="blue"><font color="blue">agreement</font>s</font>, however, will not <font color="blue">relieve us</font> of our     <font color="blue">obligation</font>  to  pay  any  royalty or <font color="blue">license fees owing at</font> the time of     <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>Our failure to retain the right to license the <font color="blue">technology</font>     underlying our proposed <font color="blue"><font color="blue">hormone therapy</font> products</font> or CaP <font color="blue">technology</font> could     harm our business and future operating results</td>
    </tr>
    <tr>
      <td>For example, if we were to     <font color="blue">enter into</font> an <font color="blue">outlicense <font color="blue">agreement</font></font> with a <font color="blue">third party</font> under which we agree     to outlicense our <font color="blue">hormone therapy</font> <font color="blue">technology</font> or CaP <font color="blue">technology</font> for a license     fee, the <font color="blue">termination</font> of the <font color="blue">main license <font color="blue">agreement</font> with</font> Antares Pharma, Inc</td>
    </tr>
    <tr>
      <td>or the <font color="blue">University </font>of California could either, depending upon the terms of     the <font color="blue">outlicense <font color="blue">agreement</font></font>, cause us to breach our <font color="blue">obligation</font>s under the     <font color="blue">outlicense <font color="blue">agreement</font></font> or give the other party a right to terminate that     <font color="blue">agreement</font>,  thereby causing us to <font color="blue">lose future revenue generated by</font> the     <font color="blue">outlicense fees</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________         We have <font color="blue">licensed two</font> of our proposed <font color="blue"><font color="blue">hormone therapy</font> products</font> to third     parties and any <font color="blue">breach by</font> these parties of their <font color="blue">obligation</font>s under these     sub<font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> or a <font color="blue">termination</font> of these sub<font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> by     these parties could <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">development</font> and marketing of our     <font color="blue">licensed products</font></td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue"><font color="blue">third parties</font> also may compete with us</font>     <font color="blue">with respect</font> to some of our <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>We  have <font color="blue">licensed two</font> of our proposed <font color="blue">hormone therapy</font> product to third     parties, Solvay Pharmaceuticals, BV and Teva Pharmaceuticals USA, Inc,     which have agreed to be responsible for continued <font color="blue">development</font>, <font color="blue">regulatory</font>     filings and <font color="blue">manufacturing</font> and marketing <font color="blue">associated with</font> the products</td>
    </tr>
    <tr>
      <td>In     addition,  we  may in the future <font color="blue">enter into</font> <font color="blue">additional</font> similar license     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">partnered products</font> that we have licensed to others are thus     subject to not only customary and inevitable <font color="blue">uncertainties</font> <font color="blue">associated with</font>     the drug <font color="blue">development</font> process, <font color="blue">regulatory</font> approvals and <font color="blue">market <font color="blue">acceptance</font></font> of     products,  but  also  depend  on  the  <font color="blue">respective licensees</font> for timely     <font color="blue">development</font>, obtaining required <font color="blue">regulatory</font> approvals, <font color="blue">commercialization</font> and     <font color="blue">otherwise continued commitment</font> to the products</td>
    </tr>
    <tr>
      <td>Our current and future     <font color="blue">licensees may</font> have <font color="blue">different</font> and, sometimes, competing priorities</td>
    </tr>
    <tr>
      <td><font color="blue">Teva USA     </font>has <font color="blue">discontinued</font> <font color="blue">development</font> of Bio-T-Gel and indicated to us a desire to     formally terminate this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are in the process of     exploring  various <font color="blue">alternative</font>s <font color="blue">with respect</font> to our Bio-T-Gel product,     including licensing the product to another <font color="blue">third party</font> or continuing the     <font color="blue">development</font> of the <font color="blue">product ourselves</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that Solvay or     any future <font color="blue">third party</font> to whom we may license our <font color="blue"><font color="blue">proposed product</font>s</font> will     remain focused on the <font color="blue">development</font> and <font color="blue">commercialization</font> of our partnered     products or will not otherwise breach the terms of our <font color="blue"><font color="blue">agreement</font>s</font> with them,     <font color="blue">especially</font> since these <font color="blue">third parties</font> may also compete with us <font color="blue">with respect</font>     to some of our <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">breach by</font> Solvay or any other third     party of their <font color="blue">obligation</font>s under these <font color="blue"><font color="blue">agreement</font>s</font> or a <font color="blue">termination</font> of these     <font color="blue"><font color="blue">agreement</font>s</font>  by these parties could <font color="blue"><font color="blue">adversely</font> affect</font> <font color="blue">development</font> of the     products in these <font color="blue"><font color="blue">agreement</font>s</font> if we are unable to sublicense the proposed     products to another party on <font color="blue">substantially</font> the same or <font color="blue">better terms</font> or     continue  the <font color="blue">development</font> and future <font color="blue">commercialization</font> of the proposed     <font color="blue">products ourselves</font></td>
    </tr>
    <tr>
      <td>We do not have any <font color="blue">facilities <font color="blue">appropriate</font></font> for <font color="blue">clinical testing</font>, we lack     <font color="blue">significant</font> <font color="blue">manufacturing</font> experience and we have very limited sales and     <font color="blue">marketing personnel</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently <font color="blue">dependent upon</font></font> our licensees or others     for several of these functions and <font color="blue">may remain <font color="blue">dependent upon</font> others</font> for     these functions</td>
    </tr>
    <tr>
      <td>We do not have a <font color="blue">manufacturing</font> facility that can be used for production of     our products</td>
    </tr>
    <tr>
      <td>In addition, at this time, we have very limited sales and     <font color="blue">marketing personnel</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently <font color="blue">dependent upon</font></font> our licensees or others     for several of these functions</td>
    </tr>
    <tr>
      <td>In the course of our <font color="blue">development</font> program, we     may be required to <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue">arrangement</font>s with other companies,     <font color="blue">universities</font>  or  clinical <font color="blue">investigators</font> for our animal testing, human     clinical  testing,  <font color="blue">manufacturing</font>  and sales and <font color="blue">marketing <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>Alternatively, we may decide to add <font color="blue">additional</font> personnel and perform some of     these functions ourselves, such as sales and <font color="blue">marketing <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>If our     licensees or other <font color="blue">third parties</font> in which we have entered into <font color="blue"><font color="blue">agreement</font>s</font>     breach their <font color="blue">obligation</font>s under our <font color="blue"><font color="blue">agreement</font>s</font> to perform these functions or     if we are <font color="blue">otherwise unable</font> to retain <font color="blue">third parties</font> for these <font color="blue">purposes on</font>     acceptable terms or perform such functions <font color="blue">successfully</font> ourselves, we may be     unable  to  <font color="blue">successfully</font>  develop, <font color="blue">manufacture</font> and market our proposed     products</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">failures by</font> our licensees or other <font color="blue">third parties</font>     to <font color="blue">adequately</font> perform their <font color="blue">responsibilities may delay</font> the submission of our     <font color="blue"><font color="blue">proposed product</font>s</font> for <font color="blue">regulatory</font> approval, impair our ability to deliver our     <font color="blue">products on</font> a <font color="blue">timely basis</font> or <font color="blue">otherwise impair</font> our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">dependence on</font> our licensees and other <font color="blue">third parties</font> for the <font color="blue">development</font>,     <font color="blue">manufacture</font>, sale and marketing of our products also may <font color="blue"><font color="blue">adversely</font> affect</font>     our <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________         Even if our <font color="blue"><font color="blue">proposed product</font>s</font> receive FDA approval, they may not achieve     expected levels of <font color="blue">market <font color="blue">acceptance</font></font>, which could have a material adverse     effect on our business, <font color="blue">financial position</font> and operating results and could     cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Even if we are able to obtain required <font color="blue">regulatory</font> approvals for our proposed     products, the success of those products is <font color="blue">dependent upon</font> <font color="blue">market <font color="blue">acceptance</font></font>     <font color="blue">by physicians</font> and patients</td>
    </tr>
    <tr>
      <td>Levels of <font color="blue">market <font color="blue">acceptance</font></font> for our <font color="blue">new products</font>     could be impacted by several factors, including:         •                   the  <font color="blue">availability</font>  of  <font color="blue">alternative</font>  products  from     <font color="blue">competitors</font>;         •                   the  price of our products relative to that of our     <font color="blue">competitors</font>;         •                  the timing of our market entry; and         •                  the ability to market our products <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">proposed product</font>s</font>     may not  achieve  expected  levels of <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Additionally,     continuing  studies  of the proper utilization, safety and efficacy of     <font color="blue"><font color="blue">pharmaceutical</font> products</font> are being <font color="blue">conducted by</font> the industry, <font color="blue">government</font>     agencies and others</td>
    </tr>
    <tr>
      <td>Such studies, which increasingly employ sophisticated     methods and <font color="blue">techniques</font>, can <font color="blue">call into question</font> the utilization, safety and     efficacy of <font color="blue">previously</font> marketed products</td>
    </tr>
    <tr>
      <td>In some cases, these studies have     resulted, and may in the future result, in the <font color="blue">discontinuance</font> of product     marketing</td>
    </tr>
    <tr>
      <td>These situations, should they occur, could have a material     adverse  effect  on  our  business,  <font color="blue">financial position</font> and results of     <font color="blue">operations</font>, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>the  <font color="blue">pharmaceutical</font>  industry  is  heavily regulated, we face     <font color="blue">significant</font> costs and <font color="blue">uncertainties</font> <font color="blue">associated with</font> our efforts to comply     with applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Should we fail to comply we could experience     material <font color="blue">adverse <font color="blue">effects on</font></font> our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font>, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is subject to <font color="blue">regulation by various federal</font> and     state  <font color="blue">government</font>al  <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>For example, we <font color="blue">must comply with</font> FDA     <font color="blue">requirements</font> <font color="blue">with respect</font> to the <font color="blue">development</font> of our <font color="blue"><font color="blue">proposed product</font>s</font> and     our <font color="blue">clinical trials</font>, and if any of our <font color="blue"><font color="blue">proposed product</font>s</font> are approved, the     <font color="blue">manufacture</font>,  labeling, sale, distribution, marketing, advertising and     promotion of our products</td>
    </tr>
    <tr>
      <td>Failure to comply with FDA and other <font color="blue">government</font>al     <font color="blue">regulations</font> can result in fines, disgorgement, unanticipated compliance     expenditures, recall or seizure of products, total or <font color="blue">partial suspension</font> of     production and/or distribution, suspension of the FDA’s review of NDAs,     enforcement actions, injunctions and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Under certain     <font color="blue">circumstances</font>, the FDA also has the authority to revoke <font color="blue">previously</font> granted     <font color="blue">drug approvals</font></td>
    </tr>
    <tr>
      <td>Despite our efforts at compliance, there is no guarantee     that we may not be deemed to be deficient in some manner in the future</td>
    </tr>
    <tr>
      <td>If     we  were  deemed to be deficient in any <font color="blue">significant</font> way, our business,     <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be <font color="blue">materially affected</font>     and the <font color="blue">market value</font> of our <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td>If we are unable to protect our <font color="blue">proprietary</font> <font color="blue">technology</font>, we may not be able     to compete as <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> places considerable <font color="blue">importance on</font> obtaining     patent  and <font color="blue">trade secret protection</font> for new <font color="blue">technologies</font>, products and     processes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, upon our ability to obtain,     enjoy and <font color="blue">enforce protection</font> for any products we develop or acquire under     <font color="blue">United States </font>and foreign patent laws and other <font color="blue">intellectual property laws</font>,     preserve  the <font color="blue">confidentiality</font> of our <font color="blue">trade secrets</font> and operate without     infringing the <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________         Where <font color="blue">appropriate</font>, we <font color="blue">seek patent protection</font> for <font color="blue"><font color="blue">certain as</font>pects</font> of our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, our owned and <font color="blue">licensed patents</font> and <font color="blue">patent <font color="blue">application</font>s</font>     may not ensure the protection of our intellectual property for a number of     other reasons:         •                  We do not know whether our licensor’s <font color="blue">patent <font color="blue">application</font>s</font>     will result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>•                  <font color="blue">Competitors </font><font color="blue">may interfere with</font> our patents and patent     process in a variety of ways</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may claim that they invented the     claimed invention before us or may claim that we are <font color="blue">infringing on</font> their     patents and therefore we <font color="blue">cannot use</font> our <font color="blue">technology</font> as claimed under our     patent</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may also have our <font color="blue">patents reexamined by showing</font> the     <font color="blue">patent examiner</font> that the invention was not original or novel or was obvious</td>
    </tr>
    <tr>
      <td>•                  We are in the <font color="blue">development</font> stage and are in the process of     developing  <font color="blue"><font color="blue">proposed product</font>s</font></td>
    </tr>
    <tr>
      <td>Even if we receive a patent, it may not     provide much <font color="blue">practical protection</font></td>
    </tr>
    <tr>
      <td>If we receive a patent with a narrow     scope, then it will be easier for <font color="blue">competitors</font> to <font color="blue">design products</font> that do not     <font color="blue">infringe on</font> our patent</td>
    </tr>
    <tr>
      <td>Even if the <font color="blue">development</font> of our <font color="blue"><font color="blue">proposed product</font>s</font> is     successful and approval for sale is obtained, there can be no assurance that     <font color="blue">applicable patent coverage</font>, if any, will not have expired or will not expire     shortly after this approval</td>
    </tr>
    <tr>
      <td>Any expiration of the <font color="blue">applicable patent could</font>     have  a  material adverse effect on the sales and <font color="blue">profitability</font> of our     <font color="blue">proposed product</font></td>
    </tr>
    <tr>
      <td>•                   <font color="blue"><font color="blue">Enforcing </font> </font>patents  is  expensive  and may require     <font color="blue">significant</font> time by our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">litigation</font>, a <font color="blue">competitor could</font> claim     that our <font color="blue">issued patents</font> are not valid for a number of reasons</td>
    </tr>
    <tr>
      <td>•                  We <font color="blue">also may support</font> and <font color="blue">collaborate</font> in <font color="blue">research conducted</font>     by <font color="blue">government</font> organizations or <font color="blue">universities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that we     will be able to acquire any <font color="blue">exclusive rights</font> to <font color="blue">technology</font> or products     <font color="blue">derived from</font> these <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>If we do not obtain required licenses or     rights, we <font color="blue">could encounter delays</font> in <font color="blue">product <font color="blue">development</font></font> while we attempt to     design  around  other patents or we may be <font color="blue">prohibited from</font> developing,     <font color="blue">manufacturing</font> or <font color="blue">selling products</font> requiring these licenses</td>
    </tr>
    <tr>
      <td>There is also a     risk that <font color="blue">disputes may</font> arise as to the rights to <font color="blue">technology</font> or products     developed in <font color="blue">collaboration with</font> other parties</td>
    </tr>
    <tr>
      <td>It also is <font color="blue">unclear whether efforts</font> to secure our <font color="blue">trade secrets</font> will provide     <font color="blue">useful protection</font></td>
    </tr>
    <tr>
      <td>While we <font color="blue">use reasonable efforts</font> to protect our trade     secrets, our employees or <font color="blue">consultants may unintentionally</font> or willfully     disclose our <font color="blue">proprietary</font> information to <font color="blue">competitors</font> resulting in a loss of     protection</td>
    </tr>
    <tr>
      <td><font color="blue">Enforcing </font>a claim that someone else illegally obtained and is     using our <font color="blue">trade secrets</font>, like patent <font color="blue">litigation</font>, is expensive and time     consuming, and the outcome is unpredictable</td>
    </tr>
    <tr>
      <td>In addition, courts outside the     <font color="blue">United States </font>are <font color="blue">sometimes less willing</font> to protect <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Finally,     our <font color="blue">competitors</font> may <font color="blue">independent</font>ly develop equivalent knowledge, methods and     know-how</td>
    </tr>
    <tr>
      <td><font color="blue">Claims  </font>by  others  that  our <font color="blue">products infringe</font> their patents or other     <font color="blue">intellectual property rights</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> has been characterized by frequent <font color="blue">litigation</font>     regarding patent and other <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">application</font>s     are maintained in secrecy in the <font color="blue">United States </font>and also are maintained in     secrecy  outside the <font color="blue">United States </font>until the <font color="blue">application</font> is published</td>
    </tr>
    <tr>
      <td>Accordingly, we can <font color="blue">conduct only</font> limited searches to determine whether our     <font color="blue">technology</font> infringes the patents or <font color="blue">patent <font color="blue">application</font>s</font> of others</td>
    </tr>
    <tr>
      <td>Any     claims  of  patent  infringement  asserted  by  <font color="blue">third parties</font> would be     time-consuming and <font color="blue">could likely</font>:                                           30     ______________________________________________________________________         •                  result in costly <font color="blue">litigation</font>;         •                  divert the time and attention of our <font color="blue">technical personnel</font>     and <font color="blue">management</font>;         •                  cause <font color="blue">product <font color="blue">development</font></font> delays;         •                  require us to develop non-infringing <font color="blue">technology</font>; or         •                  require us to <font color="blue">enter into</font> royalty or licensing <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Although patent and <font color="blue">intellectual property disputes</font> in the <font color="blue">pharmaceutical</font>     <font color="blue">industry often</font> have been settled through licensing or similar <font color="blue">arrangement</font>s,     costs  <font color="blue">associated with</font> these <font color="blue">arrangement</font>s may be substantial and often     require  the  payment of ongoing royalties, which could hurt our gross     margins</td>
    </tr>
    <tr>
      <td>In addition, we cannot be sure that the <font color="blue">necessary</font> licenses would be     available  to  us on satisfactory terms, or that we <font color="blue">could redesign</font> our     products or processes to <font color="blue">avoid infringement</font>, if <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Accordingly, an     adverse de<font color="blue">termination</font> in a judicial or <font color="blue">administrative proceeding</font>, or the     failure to obtain <font color="blue">necessary</font> licenses, could prevent us from developing,     <font color="blue">manufacturing</font>  and  selling some of our products, which could harm our     business, <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>We have very limited staffing and <font color="blue">will continue</font> to be <font color="blue"><font color="blue">dependent upon</font> key</font>     employees</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent upon</font> the efforts of a small <font color="blue">management</font> team and     staff</td>
    </tr>
    <tr>
      <td>We have <font color="blue">employment</font> <font color="blue">arrangement</font>s in place with all of our executive     officers, but none of our <font color="blue">executive officers</font> is <font color="blue">legally bound</font> to remain     employed for any <font color="blue">specific term</font></td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">key man life insurance on</font>     our President and Chief Executive Officer, Stephen M Simes, we do not have     <font color="blue">key man life insurance policies covering</font> any of our other <font color="blue">executive officers</font>     or employees</td>
    </tr>
    <tr>
      <td>If <font color="blue">key individuals leave</font> BioSante, we could be <font color="blue">adversely</font>     affected if <font color="blue">suitable replacement personnel</font> are not <font color="blue">quickly recruited</font></td>
    </tr>
    <tr>
      <td><font color="blue">On November </font>30, 2005, we <font color="blue">sent written</font> notice to Leah M Lehman, Ph</td>
    </tr>
    <tr>
      <td>D, our     former Vice President, Product Development, that we were exercising our     <font color="blue">contractual</font> right not to renew her <font color="blue">employment</font> <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Lehman’s  <font color="blue">employment</font>  <font color="blue">agreement</font>  expired  by its terms on     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">immediately</font> engaged Michael C Snabes, MD,     Ph</td>
    </tr>
    <tr>
      <td>D as an <font color="blue">independent</font> consultant to work with our <font color="blue">product <font color="blue">development</font></font> team     in <font color="blue">completion</font> of our Bio-E-Gel NDA <font color="blue">activities</font>, as well as work on <font color="blue">LibiGel     </font><font color="blue">development</font>,  it  is possible that the <font color="blue">departure</font> of Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Simes and Dr</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">competition</font> for <font color="blue">qualified personnel</font> in all functional areas, which     makes it <font color="blue">difficult</font> to attract and retain the <font color="blue">qualified personnel</font> <font color="blue">necessary</font>     for the <font color="blue">development</font> and growth of our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends</font>     upon our ability to continue to attract and retain <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We are engaged in pending legal proceedings with two <font color="blue">former employees</font> which     have caused and <font color="blue">will continue</font> to cause us to incur <font color="blue">significant</font> <font color="blue">legal fees</font>     and expenses and <font color="blue">may distract</font> our <font color="blue">management</font> from the operation of our     business</td>
    </tr>
    <tr>
      <td>Lehman’s  <font color="blue">employment</font>  <font color="blue">agreement</font>  expired  by its terms on     <font color="blue">December </font>31,  2005</td>
    </tr>
    <tr>
      <td>On  <font color="blue">February </font>15, 2006, we received notice that on     <font color="blue">February </font>10, 2006, Dr</td>
    </tr>
    <tr>
      <td>Lehman had filed a <font color="blue"><font color="blue">complaint against</font> us</font>, our Chief     Executive Officer, our <font color="blue">Chief Financial Officer </font>and one of our <font color="blue">directors</font>,     with  the  Occupational  Safety  and  Health  Administration under the     Sarbanes-Oxley Act of 2002 seeking <font color="blue">reinstatement</font> of her <font color="blue">employment</font> with back     pay, interest and attorney’s fees and claiming, among                                           31     ______________________________________________________________________         other  things,  wrongful <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">February </font>17, 2006, we filed a     <font color="blue">complaint against</font> Dr</td>
    </tr>
    <tr>
      <td>Lehman in the Circuit Court of Cook County, Illinois     alleging breach of fiduciary duty, breach of contract in regard to her     <font color="blue">employment</font>  <font color="blue">agreement</font>, tortious interference with prospective economic     advantage and abuse of process</td>
    </tr>
    <tr>
      <td>We are seeking an <font color="blue">unspecified amount</font> of     damages,  punitive damages, declaratory judgment regarding a <font color="blue">breach by</font>     Dr</td>
    </tr>
    <tr>
      <td>Lehman of her <font color="blue">employment</font> <font color="blue">agreement</font> and the amount of <font color="blue">severance pay</font>, if     any, to be owed to Dr</td>
    </tr>
    <tr>
      <td>Lehman, <font color="blue">reimbursement</font> of our <font color="blue">legal fees</font> and costs and     such other relief as the Court may deem proper</td>
    </tr>
    <tr>
      <td><font color="blue">Lehman     </font>filed a <font color="blue">charge with</font> the <font color="blue">Equal Employment Opportunity Commission </font>claiming sex     <font color="blue">discrimination</font> and <font color="blue">retaliation</font> in violation of Title VII of the Civil Rights     Act of 1964</td>
    </tr>
    <tr>
      <td>Lehman’s <font color="blue">charges with</font> the EEOC are     wholly  <font color="blue">without merit</font> and intend to <font color="blue"><font color="blue">vigorously</font> defend</font> our position</td>
    </tr>
    <tr>
      <td>In     addition,  in  January 2006, a <font color="blue">former employee filed charges</font> of sexual     harassment, gender <font color="blue">discrimination</font> and <font color="blue">retaliation</font> against us and our Chief     Executive Officer with the <font color="blue">Illinois Department of Human Rights</font></td>
    </tr>
    <tr>
      <td>Lehman’s <font color="blue">allegations</font> of wrongful <font color="blue">termination</font>, violations of the     Sarbanes-Oxley  Act,  the  EEOC  claim and the other former employee’s     <font color="blue">employment</font> related claims are wholly <font color="blue">without merit</font> and intend to <font color="blue">vigorously</font>     defend our position</td>
    </tr>
    <tr>
      <td>Such defenses, however, have caused us to incur and     will  likely  cause us to continue to incur <font color="blue">significant</font> <font color="blue">legal fees</font> and     expenses and <font color="blue">may distract</font> our <font color="blue">management</font> from the operation of our business</td>
    </tr>
    <tr>
      <td>The price and <font color="blue">trading volume</font> of our <font color="blue">common stock</font> has been, and <font color="blue">may continue</font>     to be, volatile</td>
    </tr>
    <tr>
      <td>Historically, the <font color="blue">market price</font> and <font color="blue">trading volume</font> of our <font color="blue">common stock</font> has     fluctuated over a wide range</td>
    </tr>
    <tr>
      <td>In 2005, our <font color="blue">common stock</font> traded in a range     from a low of dlra2dtta72 to a high of dlra5dtta94, and our daily <font color="blue">trading volume</font> ranged     from 8cmam900 shares to 405cmam300 shares</td>
    </tr>
    <tr>
      <td>It is likely that the price and trading     volume of our <font color="blue">common stock</font> <font color="blue">will continue</font> to fluctuate in the future</td>
    </tr>
    <tr>
      <td>The     securities of small capitalization, <font color="blue">bio<font color="blue">pharmaceutical</font></font> companies, including     our company, from time to time experience <font color="blue">significant</font> price and volume     <font color="blue">fluctuations</font>,  often  unrelated  to the operating performance of these     companies</td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">market price</font> and <font color="blue">trading volume</font> of our common     stock may fluctuate <font color="blue"><font color="blue">significant</font>ly</font> due to a variety of factors, including:         •                  <font color="blue">government</font>al agency actions, including in particular     <font color="blue">decisions</font>  or <font color="blue">actions by</font> the <font color="blue">FDA or FDA </font><font color="blue">advisory committee</font> panels with     respect to our products or our <font color="blue">competitors</font>’ products;         •                   the results of our <font color="blue">clinical trials</font> or those of our     <font color="blue">competitors</font>;         •                   <font color="blue">announcements</font>  of <font color="blue">technological innovations</font> or new     <font color="blue">products by us</font> or our <font color="blue">competitors</font>;         •                   <font color="blue">announcements</font>  by  <font color="blue">licensors</font>  or  licensees of our     <font color="blue">technology</font>;         •                  public concern as to the safety or efficacy of or market     <font color="blue">acceptance</font> of products developed by us or our <font color="blue">competitors</font>;         •                  <font color="blue">development</font>s or <font color="blue">disputes concerning patents</font> or other     <font color="blue"><font color="blue">proprietary</font> rights</font>;         •                  our ability to obtain needed financing;         •                  period-to-period <font color="blue">fluctuations</font> in our financial results,     including our cash, cash equivalents and short-term <font color="blue">investment</font> balance,     operating expenses, cash burn rate or revenues;         •                  loss of key <font color="blue">management</font>;         •                  <font color="blue">common stock</font> sales in the <font color="blue">public market by one</font> or more of     our larger stockholders, officers or <font color="blue">directors</font>;                                           32     ______________________________________________________________________         •                  other potentially negative financial <font color="blue">announcements</font>,     including delisting of our <font color="blue">common stock</font> from the American Stock Exchange,     review of any of our <font color="blue">filings by</font> the SEC, changes in <font color="blue"><font color="blue">accounting</font> treatment</font> or     <font color="blue">restatement</font>  of <font color="blue">previously</font> reported financial results or delays in our     <font color="blue">filings with</font> the SEC;         •                  <font color="blue">development</font>s in pending and any <font color="blue">future <font color="blue">litigation</font></font> of     which we may be subject; and         •                  <font color="blue">economic conditions</font> in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>In addition, the occurrence of any of the <font color="blue">risks described</font> above or elsewhere     in this report or otherwise in reports we file with or submit to the SEC     from time to time could have a material and <font color="blue">adverse impact on</font> the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example, in <font color="blue">December </font>2004, primarily as a     result of the <font color="blue">unanimous vote by</font> the FDA’s Reproductive Health Drugs Advisory     Committee <font color="blue">panel against <font color="blue">recommendation</font></font> for approval of Procter &amp; Gamble’s     Intrinsa <font color="blue">testosterone</font> patch for <font color="blue">hypoactive sexual</font> desire disorder, the price     of our <font color="blue">common stock</font> decreased over 35prca in <font color="blue">one trading day</font> and over 50prca over     the course of <font color="blue">three trading days</font></td>
    </tr>
    <tr>
      <td>In addition, on the day of and <font color="blue">first two</font>     trading  days  after  the  <font color="blue">public announcement</font> of FDA advisory panel’s     <font color="blue">recommendation</font>, the daily <font color="blue">trading volume</font> of our <font color="blue">common stock</font> went from an     average  of approximately 166cmam000 shares per day to an average of over     approximately 3 million shares per day for those <font color="blue">same three days</font> and then     <font color="blue">back down</font> to an average of approximately 140cmam000 shares per day</td>
    </tr>
    <tr>
      <td>Our current     <font color="blue">trading volume</font> is approximately 80cmam000 shares per day</td>
    </tr>
    <tr>
      <td><font color="blue">Securities </font>class action <font color="blue">litigation</font> is <font color="blue">sometimes brought against</font> a company     <font color="blue">following periods</font> of <font color="blue">volatility</font> in the <font color="blue">market price</font> of its securities or for     other reasons</td>
    </tr>
    <tr>
      <td>We may become the target of similar <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Securities </font>    <font color="blue">litigation</font>, whether with or <font color="blue">without merit</font>, could result in substantial costs     and  divert <font color="blue">management</font>’s attention and resources, which could harm our     business and <font color="blue">financial condition</font>, as well as the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain <font color="blue">effective</font> <font color="blue">internal control</font>s in <font color="blue">accordance</font>     with Section 404 of the Sarbanes-Oxley Act could have a material adverse     effect on our stock price</td>
    </tr>
    <tr>
      <td>We  are in the process of <font color="blue">documenting</font> and testing our <font color="blue">internal control</font>     procedures  in order to satisfy the <font color="blue">requirements</font> of Section 404 of the     Sarbanes-Oxley  Act  of 2002, which will become applicable <font color="blue">to BioSante     </font><font color="blue">beginning with</font> our <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2007 (or earlier, if     BioSante becomes an <font color="blue">accelerated filer under</font> the <font color="blue">Exchange Act</font>)</td>
    </tr>
    <tr>
      <td>Section 404     of the Sarbanes-Oxley Act requires annual <font color="blue">management</font> assessment of the     <font color="blue">effective</font>ness of our <font color="blue">internal control</font>s over financial reporting (ICFR) a     report by our registered <font color="blue">independent</font> public <font color="blue">accounting</font> firm <font color="blue">addressing</font>     <font color="blue">management</font>’s assessment and <font color="blue">independent</font> audit <font color="blue">of ICFR The Committee </font>of     Sponsoring  Organizations of the Treadway Commission (COSO) provides a     framework  for  companies to assess and improve their <font color="blue">internal control</font>     systems</td>
    </tr>
    <tr>
      <td>While we feel that our <font color="blue">key controls</font> are currently <font color="blue">effective</font>, we     have not yet completed a <font color="blue">formal assessment</font> of our ICFR We continue to     enhance our ICFR by adding <font color="blue">additional</font> resources in <font color="blue">key functional areas</font> and     bringing all of our <font color="blue">operations</font> up to the level of documentation, segregation     of duties, and systems security <font color="blue">necessary</font>, as well as transactional control     procedures required, under the new standard issued by the Public Company     Accounting Oversight Board</td>
    </tr>
    <tr>
      <td>We cannot be <font color="blue">certain as</font> to the timing of <font color="blue">completion</font> of our <font color="blue">evaluation</font>,     testing and <font color="blue">remediation actions</font> or their <font color="blue">effects on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we     are not able to implement the <font color="blue">requirements</font> of Section 404 in a <font color="blue">timely manner</font>     or  with  adequate  compliance,  we  might  be subject to sanctions or     <font color="blue">investigations</font>  by  <font color="blue">regulatory</font> <font color="blue">authorities</font>, such as the <font color="blue">Securities </font>and     <font color="blue">Exchange Commission or the American Stock Exchange</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such action could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our financial results, <font color="blue">financial position</font> and the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, if one or more material weaknesses     is  identified  in  ICFR, we will be unable to assert that our ICFR is     <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If we are unable to assert that our ICFR is <font color="blue">effective</font> (or if                                           33     ______________________________________________________________________         our auditors are unable to attest that <font color="blue">management</font>’s report is fairly stated,     they are unable to express an <font color="blue">opinion on</font> our <font color="blue">management</font>’s <font color="blue">evaluation</font> or on     the <font color="blue">effective</font>ness of the <font color="blue">internal control</font>s or they issue an adverse opinion     on ICFR), we could lose investor confidence in the accuracy and <font color="blue">completeness</font>     of our financial reports, which in turn could have an adverse effect on our     stock price</td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of our <font color="blue">internal control</font>s,     <font color="blue">as such standards</font> are modified, supplemented or <font color="blue">amended from</font> time to time,     we may not be able to ensure that we can conclude on an <font color="blue">ongoing basis</font> that     we have <font color="blue">effective</font> ICFR in <font color="blue">accordance</font> with Section 404 of the Sarbanes-Oxley     Act</td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain <font color="blue">effective</font> ICFR could have an adverse     effect on our <font color="blue">common stock</font> price</td>
    </tr>
  </tbody>
</table>